A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

Investigational New Drugs

Volumn 34, Issue 5, 2016, Pages 604-613

  Rosen, Lee S ^a   LoRusso, Patricia ^b   Ma, Wen Wee ^c   Goldman, Jonathan W ^a   Weise, Amy ^d   Colevas, A Dimitrios ^e   Adjei, Alex ^c   Yazji, Salim ^f,g   Shen, Angela ^f,h   Johnston, Stuart ^f,i   Hsieh, Hsin Ju ^j   Chan, Iris T ^j   Sikic, Branimir I ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YALE UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f EXELIXIS INC   (United States)

^g Baxalta US   (United States)

^h Arvinas Inc   (United States)

ⁱ NEKTAR THERAPEUTICS   (United States)

^j GENENTECH INC   (United States)

more..

Author keywords

BRAF; Cobimetinib; MEK inhibitor; Melanoma; Phase I

Indexed keywords

B RAF KINASE; COBIMETINIB; CREATINE KINASE MM; ANTINEOPLASTIC AGENT; AZETIDINE DERIVATIVE; GDC-0973; KRAS PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; COLORECTAL TUMOR; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; FATIGUE; FEMALE; GENE MUTATION; HALF LIFE TIME; HEAD TUMOR; HEPATIC ENCEPHALOPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK TUMOR; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY TUMOR; PANCREAS TUMOR; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; SOLID TUMOR; STEADY STATE; STOMACH TUMOR; STOMATITIS; SUBRETINAL FLUID; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NEOPLASM; ONCOGENE RAS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZETIDINES; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; FEMALE; GENES, RAS; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MUTATION; NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84978884221     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-016-0374-3     Document Type: Article

References (36)

1. Davies H, Bignell GR, Cox C, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954. doi:10.1111/ced.12015
2. Allen LF, Sebolt-Leopold J, Meyer MB (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30(5 Suppl 16):105–116
3. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459–65. Erratum in: Nat Rev Cancer 3:708
4. Bamford S, Dawson E, Forbes S, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91:355–358
5. Karnoub A, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9:517–531. doi:10.1038/nrm2438
6. Hoeflich KP, Merchant M, Orr C, et al. (2012) Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 72:210–219. doi:10.1158/0008-5472.CAN-11-1515
7. McCubrey JA, Steelman LS, Chappell WH, et al. (2012) Advances in targeting signal transduction pathways. Oncotarget 3:1505–1521
8. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D (2013) MEK and the inhibitors: from bench to bedside. J Hematol Oncol 6:27. doi:10.1186/1756-8722-6-27
9. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875–885
10. Solit DB, Garraway LA, Pratilas CA, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362
11. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291–3310
12. Hoeflich KP, O'Brien C, Boyd Z, et al. (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15:4649–4664. doi:10.1158/1078-0432.CCR-09-0317
13. Hatzivassiliou G, Haling JR, Chen H, et al. (2013) Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501:232–236. doi:10.1038/nature12441
14. Kim KB, Kefford R, Pavlick AC, et al. (2013) Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31:482–489. doi:10.1200/JCO.2012.43.5966
15. Falchook GS, Lewis KD, Infante JR, et al. (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782–789. doi:10.1016/S1470-2045(12)70269-3
16. Ascierto PA, Schadendorf D, Berking C, et al. (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249–256. doi:10.1016/S1470-2045(13)70024-X
17. Farley J, Brady WE, Vathipadiekal V, et al. (2013) Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14:134–140. doi:10.1016/S1470-2045(12)70572-7
18. Bekaii-Saab T, Phelps MA, Li X, et al. (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357–2363. doi:10.1200/JCO.2010.33.9473
19. Ho AL, Grewal RK, Leboeuf R, et al. (2013) Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623–632. doi:10.1056/NEJMoa1209288
20. Rosen L, LoRusso P, Ma WW et al (2011) A first-in-human Phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2–6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 71(8 Suppl):Abstract nr 4716. doi:10.1158/1538-7445.AM2011-4716
21. Wong H, Choo EF, Alicke B, et al. (2012) Antitumor activity of target and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18:3846–3855. doi:10.1158/1078-0432.CCR-12-0738
22. Choo EF, Belvin M, Boggs J, et al. (2012) Preclinical disposition of gdc-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab Dispos 40:919–927. doi:10.1124/dmd.111.043778
23. Young H, Baum R, Cremerius U et al.; European Organization for Research and Treatment of cancer (EORTC) PET study group (1999) measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 35:1773–82
24. Binns DS, Pirzkall A, Yu W et al.; OSI3926g Study Team (2011) Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 38:642. doi:10.1007/s00259-010-1665-0
25. Patel R, Tsan A, Tam R, et al. (2012) Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel. PLoS One 7:e51153. doi:10.1371/journal.pone.0051153
26. Therasse P, Arbuck SG, Eisenhauer EA et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–16
27. LoRusso PM, Adjei AA, Varterasian M, et al. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281–5293
28. Martinez-Garcia M, Banerji U, Albanell J, et al. (2012) First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 18:4806–4819
29. Infante JR, Fecher LA, Falchook GS, et al. (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773–781. doi:10.1016/S1470-2045(12)70270-X
30. Honda K, Yamamoto N, Nokihara H, et al. (2013) Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 72:577–584. doi:10.1007/s00280-013-2228-4
31. Ribas A, Gonzalez R, Pavlick A, et al. (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 15:954–965. doi:10.1016/S1470-2045(14)70301-8
32. Larkin J, Ascierto PA, Dréno B, et al. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867–1876. doi:10.1056/NEJMoa1408868
33. Flaherty KT, Robert C, Hersey P et al.; METRIC Study Group (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–14. doi:10.1056/NEJMoa1203421
34. Catalanotti F, Solit DB, Pulitzer MP, et al. (2013) Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 19:2257–2264. doi:10.1158/1078-0432.CCR-12-3476
35. Weekes CD, Von Hoff DD, Adjei AA, et al. (2013) Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86–9766 in patients with advanced cancer. Clin Cancer Res 19:1232–1243. doi:10.1158/1078-0432.CCR-12-3529
36. Bennouna J, Lang I, Valladares-Ayerbes M, et al. (2011) A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Investig New Drugs 29:1021–1028. doi:10.1007/s10637-010-9392-8